These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 29352318)

  • 21. Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors.
    Wang Z; Yang J; Xu G; Wang W; Liu C; Yang H; Yu Z; Lei Q; Xiao L; Xiong J; Zeng L; Xiang J; Ma J; Li G; Wu M
    Oncotarget; 2015 Feb; 6(5):3147-64. PubMed ID: 25605243
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
    Li H; Li J; Cheng G; Zhang J; Li X
    Clin Neurol Neurosurg; 2016 Dec; 151():31-36. PubMed ID: 27764705
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomimetic brain tumor niche regulates glioblastoma cells towards a cancer stem cell phenotype.
    Liu YC; Lee IC; Chen PY
    J Neurooncol; 2018 May; 137(3):511-522. PubMed ID: 29357090
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.
    Cheng ZX; Yin WB; Wang ZY
    Int J Mol Med; 2017 Nov; 40(5):1307-1314. PubMed ID: 28901390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR amplified and overexpressing glioblastomas and association with better response to adjuvant metronomic temozolomide.
    Cominelli M; Grisanti S; Mazzoleni S; Branca C; Buttolo L; Furlan D; Liserre B; Bonetti MF; Medicina D; Pellegrini V; Buglione M; Liserre R; Pellegatta S; Finocchiaro G; Dalerba P; Facchetti F; Pizzi M; Galli R; Poliani PL
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25739547
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon-α/β enhances temozolomide activity against MGMT-positive glioma stem-like cells.
    Shen D; Guo CC; Wang J; Qiu ZK; Sai K; Yang QY; Chen YS; Chen FR; Wang J; Panasci L; Chen ZP
    Oncol Rep; 2015 Nov; 34(5):2715-21. PubMed ID: 26329778
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
    Ramirez YP; Mladek AC; Phillips RM; Gynther M; Rautio J; Ross AH; Wheelhouse RT; Sakaria JN
    Mol Cancer Ther; 2015 Jan; 14(1):111-9. PubMed ID: 25351918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intratumoral hypoxic gradient drives stem cells distribution and MGMT expression in glioblastoma.
    Pistollato F; Abbadi S; Rampazzo E; Persano L; Della Puppa A; Frasson C; Sarto E; Scienza R; D'avella D; Basso G
    Stem Cells; 2010 May; 28(5):851-62. PubMed ID: 20309962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cancer Stem Cells and Chemoresistance in Glioblastoma Multiform: A Review Article.
    Safari M; Khoshnevisan A
    J Stem Cells; 2015; 10(4):271-85. PubMed ID: 27144829
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clonal evolution of glioblastoma under therapy.
    Wang J; Cazzato E; Ladewig E; Frattini V; Rosenbloom DI; Zairis S; Abate F; Liu Z; Elliott O; Shin YJ; Lee JK; Lee IH; Park WY; Eoli M; Blumberg AJ; Lasorella A; Nam DH; Finocchiaro G; Iavarone A; Rabadan R
    Nat Genet; 2016 Jul; 48(7):768-76. PubMed ID: 27270107
    [TBL] [Abstract][Full Text] [Related]  

  • 31. microRNA expression pattern modulates temozolomide response in GBM tumors with cancer stem cells.
    Tezcan G; Tunca B; Bekar A; Preusser M; Berghoff AS; Egeli U; Cecener G; Ricken G; Budak F; Taskapılıoglu MO; Kocaeli H; Tolunay S
    Cell Mol Neurobiol; 2014 Jul; 34(5):679-92. PubMed ID: 24691539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical and Genetic Factors Associated With Severe Hematological Toxicity in Glioblastoma Patients During Radiation Plus Temozolomide Treatment: A Prospective Study.
    Lombardi G; Rumiato E; Bertorelle R; Saggioro D; Farina P; Della Puppa A; Zustovich F; Berti F; Sacchetto V; Marcato R; Amadori A; Zagonel V
    Am J Clin Oncol; 2015 Oct; 38(5):514-9. PubMed ID: 24064758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Synergistic Effect of Combination Progesterone and Temozolomide on Human Glioblastoma Cells.
    Atif F; Patel NR; Yousuf S; Stein DG
    PLoS One; 2015; 10(6):e0131441. PubMed ID: 26110872
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide.
    McFaline-Figueroa JL; Braun CJ; Stanciu M; Nagel ZD; Mazzucato P; Sangaraju D; Cerniauskas E; Barford K; Vargas A; Chen Y; Tretyakova N; Lees JA; Hemann MT; White FM; Samson LD
    Cancer Res; 2015 Aug; 75(15):3127-38. PubMed ID: 26025730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chemoresistance of glioblastoma cancer stem cells--much more complex than expected.
    Beier D; Schulz JB; Beier CP
    Mol Cancer; 2011 Oct; 10():128. PubMed ID: 21988793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Error-Prone DNA Polymerase κ Promotes Temozolomide Resistance in Glioblastoma through Rad17-Dependent Activation of ATR-Chk1 Signaling.
    Peng C; Chen Z; Wang S; Wang HW; Qiu W; Zhao L; Xu R; Luo H; Chen Y; Chen D; You Y; Liu N; Wang H
    Cancer Res; 2016 Apr; 76(8):2340-53. PubMed ID: 26960975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
    Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.
    Gállego Pérez-Larraya J; Ducray F; Chinot O; Catry-Thomas I; Taillandier L; Guillamo JS; Campello C; Monjour A; Cartalat-Carel S; Barrie M; Huchet A; Beauchesne P; Matta M; Mokhtari K; Tanguy ML; Honnorat J; Delattre JY
    J Clin Oncol; 2011 Aug; 29(22):3050-5. PubMed ID: 21709196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A concurrent ultra-fractionated radiation therapy and temozolomide treatment: A promising therapy for newly diagnosed, inoperable glioblastoma.
    Beauchesne P; Quillien V; Faure G; Bernier V; Noel G; Quetin P; Gorlia T; Carnin C; Pedeux R
    Int J Cancer; 2016 Mar; 138(6):1538-44. PubMed ID: 26501997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.